Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
lidocaine and prilocaine cream
Overview
What is Priloxx LP External Kit?
Lidocaine 2.5% and Prilocaine 2.5% Cream, USP is an emulsion in which the oil phase is a eutectic
mixture of lidocaine and prilocaine cream in a ratio of 1:1 by weight. This eutectic mixture has a
melting point below room temperature and therefore both local anesthetics exist as a liquid oil rather
than as crystals. It is packaged in 5 gram and 30 gram tubes.
Lidocaine is chemically designated as acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl), has an
octanol: water partition ratio of 43 at pH 7.4, and has the following structure:
Each gram of lidocaine and prilocaine cream contains lidocaine 25 mg, prilocaine 25 mg,
polyoxyethylene fatty acid esters (as emulsifiers), carboxypolymethylene (as a thickening agent),
sodium hydroxide to adjust to a pH approximating 9, and purified water to 1 gram. Lidocaine and
prilocaine cream contains no preservative, however it passes the USP antimicrobial effectiveness test
due to the pH. The specific gravity of lidocaine and prilocaine cream is 1.00.
What does Priloxx LP External Kit look like?
What are the available doses of Priloxx LP External Kit?
Sorry No records found.
What should I talk to my health care provider before I take Priloxx LP External Kit?
Sorry No records found
How should I use Priloxx LP External Kit?
Lidocaine and prilocaine cream (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated
as a topical anesthetic for use on:
- normal intact skin for local analgesia.
- genital mucous membranes for superficial minor surgery and as pretreatment for infiltration
anesthesia.
Lidocaine and prilocaine cream is not recommended in any clinical situation when penetration or
migration beyond the tympanic membrane into the middle ear is possible because of the ototoxic effects
observed in animal studies (see WARNINGS).
Adult Patients -Intact Skin
Minor Dermal Procedures
Adult Male Genital Skin:
Adult Female Patients -Genital Mucous Membranes
Pediatric Patients -Intact Skin
What interacts with Priloxx LP External Kit?
Lidocaine and prilocaine cream (lidocaine 2.5% and prilocaine 2.5%) is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type or to any other component of the product.
What are the warnings of Priloxx LP External Kit?
As with other agents which have anticonvulsant activity, when diazepam is used as an adjunct in treating convulsive disorders, the possibility of an increase in the frequency and/or severity of grand mal seizures may require an increase in the dosage of standard anticonvulsant medication. Abrupt withdrawal of diazepam in such cases may also be associated with a temporary increase in the frequency and/or severity of seizures.
What are the precautions of Priloxx LP External Kit?
Sorry No Records found
What are the side effects of Priloxx LP External Kit?
Localized Reactions : During or immediately after treatment with lidocaine and prilocaine cream on
intact skin, the skin at the site of treatment may develop erythema or edema or may be the locus of
abnormal sensation. Rare cases of discrete purpuric or petechial reactions at the application site have
been reported. Rare cases of hyperpigmentation following the use of lidocaine and prilocaine cream
have been reported. The relationship to lidocaine and prilocaine cream or the underlying procedure has
not been established. In clinical studies on intact skin involving over 1,300 lidocaine and prilocaine
cream-treated subjects, one or more such local reactions were noted in 56% of patients, and were
generally mild and transient, resolving spontaneously within 1 or 2 hours. There were no serious
reactions that were ascribed to lidocaine and prilocaine cream.
Array
Array
Array
Array
Array
What should I look out for while using Priloxx LP External Kit?
Lidocaine and prilocaine cream (lidocaine 2.5% and prilocaine 2.5%) is contraindicated in patients with
a known history of sensitivity to local anesthetics of the amide type or to any other component of the
product.
Application of lidocaine and prilocaine cream to larger areas or for longer times than those
recommended could result in sufficient absorption of lidocaine and prilocaine resulting in serious
adverse effects (see Individualization of Dose).
Patients treated with class III anti-arrhythmic drugs (e.g., amiodarone, bretylium, sotalol, dofetilide)
should be under close surveillance and ECG monitoring considered, because cardiac effects may be
additive.
Studies in laboratory animals (guinea pigs) have shown that lidocaine and prilocaine cream has an
ototoxic effect when instilled into the middle ear. In these same studies, animals exposed to lidocaine
and prilocaine cream only in the external auditory canal, showed no abnormality. Lidocaine and
prilocaine cream should not be used in any clinical situation when its penetration or migration beyond
the tympanic membrane into the middle ear is possible.
Methemoglobinemia: Lidocaine and prilocaine cream should not be used in those rare patients with
congenital or idiopathic methemoglobinemia and in infants under the age of twelve months who are
receiving treatment with methemoglobin-inducing agents.
Very young patients or patients with glucose-6-phosphate dehydrogenase deficiencies are more
susceptible to methemoglobinemia.
Patients taking drugs associated with drug-induced methemoglobinemia such as sulfonamides,
acetaminophen, acetanilid, aniline dyes, benzocaine, chloroquine, dapsone, naphthalene, nitrates and
nitrites, nitrofurantoin, nitroglycerin, nitroprusside, pamaquine, para-aminosalicylic acid, phenacetin,
phenobarbital, phenytoin, primaquine, quinine, are also at greater risk for developing
methemoglobinemia.
There have been reports of significant methemoglobinemia (20 to 30%) in infants and children
following excessive applications of lidocaine and prilocaine cream. These cases involved the use of
large doses, larger than recommended areas of application, or infants under the age of 3 months who did
not have fully mature enzyme systems. In addition, a few of these cases involved the concomitant
administration of methemoglobin-inducing agents. Most patients recovered spontaneously after removal
of the cream. Treatment with IV methylene blue may be effective if required.
Physicians are cautioned to make sure that parents orother caregivers understand the need for careful
application of lidocaine and prilocaine cream, to ensure that the doses and areas of application
recommended in Table 2 are not exceeded (especially in children under the age of 3 months) and to limit
the period of application to the minimum required to achieve the desired anesthesia.
Neonates and infants up to 3 months of age should be monitored for Met-Hb levels before, during, and
after the application of lidocaine and prilocaine cream, provided the test results can be obtained quickly.
What might happen if I take too much Priloxx LP External Kit?
Peak blood levels following a 60 g application to 400 cm of intact skin for 3 hours are 0.05 to 0.16
μg/mL for lidocaine and 0.02 to 0.10 μg/mL for prilocaine. Toxic levels of lidocaine (>5 μg/mL) and/or
prilocaine (>6 μg/mL) cause decreases in cardiac output, total peripheral resistance and mean arterial
pressure. These changes may be attributable to direct depressant effects of these local anesthetic agents
on the cardiovascular system. In the absence of massive topical overdose or oral ingestion, evaluation
should include evaluation of other etiologies for the clinical effects or overdosage from other sources
of lidocaine, prilocaine or other local anesthetics. Consult the package inserts for parenteral Xylocaine
(lidocaine HCl) or Citanest (prilocaine HCl) for further information for the management of overdose.
How should I store and handle Priloxx LP External Kit?
ArrayPriloxx LP External Pak (Lidocaine 2.5% and Prilocaine 2.5% Cream, USP) with OcclusiveDressing Contains:NOT FOR OPHTHALMIC USE. KEEP CONTAINER TIGHTLY CLOSED AT ALL TIMES WHEN NOT IN USE. Rx only Keep out of the reach of children Priloxx LP External Pak (Lidocaine 2.5% and Prilocaine 2.5% Cream, USP) with OcclusiveDressing Contains:NOT FOR OPHTHALMIC USE. KEEP CONTAINER TIGHTLY CLOSED AT ALL TIMES WHEN NOT IN USE. Rx only Keep out of the reach of children Priloxx LP External Pak (Lidocaine 2.5% and Prilocaine 2.5% Cream, USP) with OcclusiveDressing Contains:NOT FOR OPHTHALMIC USE. KEEP CONTAINER TIGHTLY CLOSED AT ALL TIMES WHEN NOT IN USE. Rx only Keep out of the reach of children Priloxx LP External Pak (Lidocaine 2.5% and Prilocaine 2.5% Cream, USP) with OcclusiveDressing Contains:NOT FOR OPHTHALMIC USE. KEEP CONTAINER TIGHTLY CLOSED AT ALL TIMES WHEN NOT IN USE. Rx only Keep out of the reach of children
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Mechanism of Action
Dermal application of lidocaine and prilocaine cream may cause a transient, local blanching followed by
a transient, local redness or erythema.
: Lidocaine and prilocaine cream is a eutectic mixture of lidocaine 2.5% and
prilocaine 2.5% formulated as an oil in water emulsion. In this eutectic mixture, both anesthetics are
liquid at room temperature (see DESCRIPTION) and the penetration and subsequent systemic absorption
of both prilocaine and lidocaine are enhanced over that which would be seen if each component in
crystalline form was applied separately as a 2.5% topical cream.
Absorption
Distribution
Metabolism
Elimination
Pediatrics
Special Populations
Non-Clinical Toxicology
Lidocaine and prilocaine cream (lidocaine 2.5% and prilocaine 2.5%) is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type or to any other component of the product.Application of lidocaine and prilocaine cream to larger areas or for longer times than those recommended could result in sufficient absorption of lidocaine and prilocaine resulting in serious adverse effects (see Individualization of Dose). Patients treated with class III anti-arrhythmic drugs (e.g., amiodarone, bretylium, sotalol, dofetilide) should be under close surveillance and ECG monitoring considered, because cardiac effects may be additive. Studies in laboratory animals (guinea pigs) have shown that lidocaine and prilocaine cream has an ototoxic effect when instilled into the middle ear. In these same studies, animals exposed to lidocaine and prilocaine cream only in the external auditory canal, showed no abnormality. Lidocaine and prilocaine cream should not be used in any clinical situation when its penetration or migration beyond the tympanic membrane into the middle ear is possible. Methemoglobinemia: Lidocaine and prilocaine cream should not be used in those rare patients with congenital or idiopathic methemoglobinemia and in infants under the age of twelve months who are receiving treatment with methemoglobin-inducing agents. Very young patients or patients with glucose-6-phosphate dehydrogenase deficiencies are more susceptible to methemoglobinemia. Patients taking drugs associated with drug-induced methemoglobinemia such as sulfonamides, acetaminophen, acetanilid, aniline dyes, benzocaine, chloroquine, dapsone, naphthalene, nitrates and nitrites, nitrofurantoin, nitroglycerin, nitroprusside, pamaquine, para-aminosalicylic acid, phenacetin, phenobarbital, phenytoin, primaquine, quinine, are also at greater risk for developing methemoglobinemia. There have been reports of significant methemoglobinemia (20 to 30%) in infants and children following excessive applications of lidocaine and prilocaine cream. These cases involved the use of large doses, larger than recommended areas of application, or infants under the age of 3 months who did not have fully mature enzyme systems. In addition, a few of these cases involved the concomitant administration of methemoglobin-inducing agents. Most patients recovered spontaneously after removal of the cream. Treatment with IV methylene blue may be effective if required. Physicians are cautioned to make sure that parents orother caregivers understand the need for careful application of lidocaine and prilocaine cream, to ensure that the doses and areas of application recommended in Table 2 are not exceeded (especially in children under the age of 3 months) and to limit the period of application to the minimum required to achieve the desired anesthesia. Neonates and infants up to 3 months of age should be monitored for Met-Hb levels before, during, and after the application of lidocaine and prilocaine cream, provided the test results can be obtained quickly.
Many drugs affect thyroid hormone pharmacokinetics and metabolism (e.g., absorption, synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to Levothyroxine Sodium Tablets, USP. In addition, thyroid hormones and thyroid status have varied effects on the pharmacokinetics and action of other drugs. A listing of drug-thyroidal axis interactions is contained in Table 2.
The list of drug-thyroidal axis interactions in Table 2 may not be comprehensive due to the introduction of new drugs that interact with the thyroidal axis or the discovery of previously unknown interactions. The prescriber should be aware of this fact and should consult appropriate reference sources (e.g., package inserts of newly approved drugs, medical literature) for additional information if a drug-drug interaction with levothyroxine is suspected.
General
Information for Patients
Drug Interactions
Prilocaine may contribute to the formation of methemoglobin in patients treated with other drugs known to cause this condition
Carcinogenesis , Mutagenesis , Impairment of Fertility
Carcinogenesis
Mutagenesis
Ortho
Escherichia coli
Salmonella typhimurium
Impairment of Fertility
Use in Pregnancy
Teratogenic Effects : Pregnancy Category B
Labor and Delivery
Nursing Mothers
Pediatric Use
In neonates (minimum ges tation age: 37 weeks ) and children weighing les s than 20 kg, the area and duration of application should be limited
Geriatric Use
Localized Reactions : During or immediately after treatment with lidocaine and prilocaine cream on intact skin, the skin at the site of treatment may develop erythema or edema or may be the locus of abnormal sensation. Rare cases of discrete purpuric or petechial reactions at the application site have been reported. Rare cases of hyperpigmentation following the use of lidocaine and prilocaine cream have been reported. The relationship to lidocaine and prilocaine cream or the underlying procedure has not been established. In clinical studies on intact skin involving over 1,300 lidocaine and prilocaine cream-treated subjects, one or more such local reactions were noted in 56% of patients, and were generally mild and transient, resolving spontaneously within 1 or 2 hours. There were no serious reactions that were ascribed to lidocaine and prilocaine cream.
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).